Telomere Length Change in a Multidomain Lifestyle Intervention to Prevent Cognitive Decline: A Randomized Clinical Trial.
Behavioral intervention
Dementia prevention
Older adults
Telomeres
Journal
The journals of gerontology. Series A, Biological sciences and medical sciences
ISSN: 1758-535X
Titre abrégé: J Gerontol A Biol Sci Med Sci
Pays: United States
ID NLM: 9502837
Informations de publication
Date de publication:
25 02 2021
25 02 2021
Historique:
received:
07
04
2020
pubmed:
12
11
2020
medline:
23
7
2021
entrez:
11
11
2020
Statut:
ppublish
Résumé
Shorter leukocyte telomere length (LTL) is associated with aging and dementia. Impact of lifestyle changes on LTL, and relation to cognition and genetic susceptibility for dementia, has not been investigated in randomized controlled trials (RCTs). Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability is a 2-year RCT enrolling 1260 participants at risk for dementia from the general population, aged 60-77 years, randomly assigned (1:1) to multidomain lifestyle intervention or control group. The primary outcome was cognitive change (Neuropsychological Test Battery z-score). Relative LTL was measured using quantitative real-time polymerase chain reaction (trial registration: NCT01041989). This exploratory LTL substudy included 756 participants (377 intervention, 379 control) with baseline and 24-month LTL measurements. The mean annual LTL change (SD) was -0.016 (0.19) in the intervention group and -0.023 (0.17) in the control group. Between-group difference was nonsignificant (unstandardized β-coefficient 0.007, 95% CI -0.015 to 0.030). Interaction analyses indicated better LTL maintenance among apolipoprotein E (APOE)-ε4 carriers versus noncarriers: 0.054 (95% CI 0.007 to 0.102); younger versus older participants: -0.005 (95% CI -0.010 to -0.001); and those with more versus less healthy lifestyle changes: 0.047 (95% CI 0.005 to 0.089). Cognitive intervention benefits were more pronounced among participants with better LTL maintenance for executive functioning (0.227, 95% CI 0.057 to 0.396) and long-term memory (0.257, 95% CI 0.024 to 0.489), with a similar trend for Neuropsychological Test Battery total score (0.127, 95% CI -0.011 to 0.264). This is the first large RCT showing that a multidomain lifestyle intervention facilitated LTL maintenance among subgroups of older people at risk for dementia, including APOE-ε4 carriers. LTL maintenance was associated with more pronounced cognitive intervention benefits. NCT01041989.
Sections du résumé
BACKGROUND
Shorter leukocyte telomere length (LTL) is associated with aging and dementia. Impact of lifestyle changes on LTL, and relation to cognition and genetic susceptibility for dementia, has not been investigated in randomized controlled trials (RCTs).
METHODS
Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability is a 2-year RCT enrolling 1260 participants at risk for dementia from the general population, aged 60-77 years, randomly assigned (1:1) to multidomain lifestyle intervention or control group. The primary outcome was cognitive change (Neuropsychological Test Battery z-score). Relative LTL was measured using quantitative real-time polymerase chain reaction (trial registration: NCT01041989).
RESULTS
This exploratory LTL substudy included 756 participants (377 intervention, 379 control) with baseline and 24-month LTL measurements. The mean annual LTL change (SD) was -0.016 (0.19) in the intervention group and -0.023 (0.17) in the control group. Between-group difference was nonsignificant (unstandardized β-coefficient 0.007, 95% CI -0.015 to 0.030). Interaction analyses indicated better LTL maintenance among apolipoprotein E (APOE)-ε4 carriers versus noncarriers: 0.054 (95% CI 0.007 to 0.102); younger versus older participants: -0.005 (95% CI -0.010 to -0.001); and those with more versus less healthy lifestyle changes: 0.047 (95% CI 0.005 to 0.089). Cognitive intervention benefits were more pronounced among participants with better LTL maintenance for executive functioning (0.227, 95% CI 0.057 to 0.396) and long-term memory (0.257, 95% CI 0.024 to 0.489), with a similar trend for Neuropsychological Test Battery total score (0.127, 95% CI -0.011 to 0.264).
CONCLUSIONS
This is the first large RCT showing that a multidomain lifestyle intervention facilitated LTL maintenance among subgroups of older people at risk for dementia, including APOE-ε4 carriers. LTL maintenance was associated with more pronounced cognitive intervention benefits.
CLINICAL TRIALS REGISTRATION NUMBER
NCT01041989.
Identifiants
pubmed: 33175128
pii: 5974120
doi: 10.1093/gerona/glaa279
pmc: PMC7907495
doi:
Banques de données
ClinicalTrials.gov
['NCT01041989']
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
491-498Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of The Gerontological Society of America.
Références
Transl Psychiatry. 2017 Apr 18;7(4):e1100
pubmed: 28418400
Neurology. 1989 Sep;39(9):1159-65
pubmed: 2771064
Lancet. 2015 Jun 6;385(9984):2255-63
pubmed: 25771249
Science. 2008 Jun 13;320(5882):1510-2
pubmed: 18556560
Nutrition. 2014 Apr;30(4):489-91
pubmed: 24342530
J Gerontol A Biol Sci Med Sci. 2014 Jun;69 Suppl 1:S10-6
pubmed: 24833580
Neurobiol Aging. 2011 Nov;32(11):2055-60
pubmed: 20031273
Alzheimers Dement. 2013 Nov;9(6):657-65
pubmed: 23332672
J Med Genet. 2015 May;52(5):297-302
pubmed: 25770094
Sleep Med. 2013 Mar;14(3):229-36
pubmed: 23352029
PLoS One. 2010 May 25;5(5):e10826
pubmed: 20520834
PLoS One. 2012;7(9):e45166
pubmed: 23028820
Lancet Neurol. 2006 Sep;5(9):735-41
pubmed: 16914401
Neurobiol Aging. 2010 Jun;31(6):986-92
pubmed: 18718693
Nutrients. 2018 Oct 21;10(10):
pubmed: 30347863
JAMA Neurol. 2018 Apr 1;75(4):462-470
pubmed: 29356827
Arch Neurol. 2007 Sep;64(9):1323-9
pubmed: 17846273
Ageing Res Rev. 2013 Mar;12(2):509-19
pubmed: 23333817
Aging Cell. 2009 Aug;8(4):405-13
pubmed: 19493248
J Gerontol A Biol Sci Med Sci. 2017 Dec 12;73(1):39-47
pubmed: 28510637
Exp Gerontol. 2012 Feb;47(2):179-82
pubmed: 22210159
Lancet Oncol. 2013 Oct;14(11):1112-1120
pubmed: 24051140
Trends Neurosci. 2014 May;37(5):256-63
pubmed: 24698125
J Gerontol A Biol Sci Med Sci. 2012 Apr;67(4):330-5
pubmed: 22016362
PLoS One. 2012;7(4):e34948
pubmed: 22493726
PLoS One. 2012;7(5):e38374
pubmed: 22675460
Nucleic Acids Res. 2002 May 15;30(10):e47
pubmed: 12000852
Neurobiol Aging. 2012 Feb;33(2):335-44
pubmed: 20395015
J Gerontol A Biol Sci Med Sci. 2016 Aug;71(8):1069-73
pubmed: 27091133
Psychoneuroendocrinology. 2014 Apr;42:45-8
pubmed: 24636500
Mutat Res. 2012 Feb 1;730(1-2):85-9
pubmed: 21878343
Science. 2015 Dec 4;350(6265):1193-8
pubmed: 26785477
Mol Psychiatry. 2015 Apr;20(4):529-35
pubmed: 25070535
J Cell Mol Med. 2008 Dec;12(6B):2762-71
pubmed: 18318693
J Gerontol A Biol Sci Med Sci. 2012 Apr;67(4):409-16
pubmed: 21934123
Aging (Albany NY). 2016 Jul;8(7):1398-415
pubmed: 27391763
Age Ageing. 2013 Jul;42(4):450-5
pubmed: 23519133